Joe Lennerz

Dr. Joe Lennerz, Chief Scientific Officer of BostonGene and an expert in gastrointestinal and liver pathology, simplifies next-generation sequencing (NGS) for listeners. He discusses who benefits from NGS and its implications for treatment, including the challenges surrounding minimal residual disease (MRD) detection and liquid biopsies. The conversation also delves into the future of multi-cancer early detection technologies and the necessity for regulatory oversight in this fast-evolving field of healthcare innovation.